Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decernotinib Monotherapy in Active Rheumatoid Arthritis
NCT01052194Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of decernotinib in rheumatoid arthritis (RA), sponsored by Vertex Pharmaceuticals. Started Feb 2010; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01052194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052194.